Diamyd Medical Ab Stock Net Asset
| DMN Stock | EUR 0.71 0.02 2.74% |
Diamyd Medical AB fundamentals help investors to digest information that contributes to Diamyd Medical's financial success or failures. It also enables traders to predict the movement of Diamyd Stock. The fundamental analysis module provides a way to measure Diamyd Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diamyd Medical stock.
Diamyd |
Diamyd Medical AB Company Net Asset Analysis
Diamyd Medical's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Diamyd Medical Net Asset | 236.52 M |
Most of Diamyd Medical's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diamyd Medical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Diamyd Medical AB has a Net Asset of 236.52 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all Germany stocks is notably lower than that of the firm.
Diamyd Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diamyd Medical's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diamyd Medical could also be used in its relative valuation, which is a method of valuing Diamyd Medical by comparing valuation metrics of similar companies.Diamyd Medical is currently under evaluation in net asset category among its peers.
Diamyd Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 96.81 M | |||
| Shares Outstanding | 76.93 M | |||
| Shares Owned By Insiders | 35.22 % | |||
| Shares Owned By Institutions | 0.26 % | |||
| Price To Book | 5.52 X | |||
| Price To Sales | 2,594 X | |||
| Revenue | 454 K | |||
| Gross Profit | (3.95 M) | |||
| EBITDA | (98.88 M) | |||
| Net Income | (103.52 M) | |||
| Current Ratio | 5.83 X | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (93.22 M) | |||
| Earnings Per Share | (0.11) X | |||
| Target Price | 19.0 | |||
| Number Of Employees | 20 | |||
| Beta | 1.91 | |||
| Market Capitalization | 99.6 M | |||
| Total Asset | 236.52 M | |||
| Net Asset | 236.52 M |
About Diamyd Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diamyd Medical AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diamyd Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diamyd Medical AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.